Advertisement

Annals of Surgical Oncology

, Volume 12, Issue 12, pp 957–959 | Cite as

Tumor Regression and Autoimmunity in CytotoxicT Lymphocyte–Associated Antigen 4 Blockade–Treated Patients

  • Jeffrey S. Weber
Editorial

Progress in cancer immunotherapy has been modest in the last two decades since interleukin (IL)-2 was shown to induce long-term sustained responses in a proportion of patients with melanoma and renal cell cancer.1,2 That cytokine was approved in the late 1990s by the US Food and Drug Administration for the treatment of stage IV renal cell cancer and melanoma. The exact mechanism of action by which IL-2 mediates regression of melanoma is unknown. Various empiric combinations of agents active in melanoma have been tested with IL-2, including chemotherapy agents and other cytokines,3,4 without a clear benefit in overall survival. The article by Maker et al.5 in this issue of Annals of Surgical Oncology describes a study of immunotherapy with high-dose IL-2 combined with a novel antibody that abrogates the effects of cytotoxic T lymphocyte–associated antigen 4 (CTLA-4) in patients with stage IV melanoma.6The CTLA-4 molecule is expressed on activated T cells and competes with coactivator...

Keywords

Melanoma Renal Cell Cancer Peptide Vaccine Small Pilot Trial Autoimmune Toxicity 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Atkins MB, Lotze MT, Dutcher JP, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 1999;17:2105–16PubMedGoogle Scholar
  2. 2.
    Fyfe GA, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie AC. Long-term response data for 255 patients with metastatic renal cell carcinoma treated with high-dose recombinant interleukin-2 therapy. J Clin Oncol 1996;14:2410–1PubMedGoogle Scholar
  3. 3.
    Flaherty LE, Atkins M, Sosman J, et al. Outpatient biochemotherapy with interleukin-2 and interferon alfa-2b in patients with metastatic malignant melanoma: results of two phase II cytokine working group trials. J Clin Oncol 2001;19:3194–202PubMedGoogle Scholar
  4. 4.
    O’Day SJ, Boasberg PD, Piro L, et al. Maintenance biotherapy for metastatic melanoma with interleukin-2 and granulocyte macrophage-colony stimulating factor improves survival for patients responding to induction concurrent biochemotherapy. Clin Cancer Res 2002;8:2775–81PubMedGoogle Scholar
  5. 5.
    Maker AV, Phan GQ, Attia P, et al. Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte–associated antigen 4 blockade and interleukin 2: a phase I/II study. Ann Surg Oncol (in press)Google Scholar
  6. 6.
    Linsley PS, Brady W, Urnes M, Grosmaire MLS, Damle NK, Ledbetter JA. CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med 1991;174:561–9CrossRefPubMedGoogle Scholar
  7. 7.
    Hodi FS, Mihm MC, Soiffer RJ, et al. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci U S A 2003;100:4712–7CrossRefPubMedGoogle Scholar
  8. 8.
    Phan GQ, Yang JC, Sherry RM, et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A 2003;100:8372–7CrossRefPubMedGoogle Scholar
  9. 9.
    Sanderson K, Scotland R, Lee P, et al. Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma. J Clin Oncol 2005;23:741–50PubMedGoogle Scholar
  10. 10.
    Tivol EA, Borriello F, Schweitzer AN, Lynch WP, Bluestone JA, Sharpe AH. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role for CTLA-4. Immunity 1995;3:541–6CrossRefPubMedGoogle Scholar
  11. 11.
    Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science 1996;2671:1734–6Google Scholar
  12. 12.
    Lute KD, May KF, Lu P, et al. Human CTLA-4-knock-in mice unravel the quantitative link between tumor immunity and autoimmunity induced by anti-CTLA-4 antibodies. Blood 2005 (in press)Google Scholar

Copyright information

© The Society of Surgical Oncology, Inc. 2005

Authors and Affiliations

  1. 1.Norris Cancer Center, University of Southern CaliforniaLos Angeles

Personalised recommendations